In vivo selective cancer-tracking gadolinium eradicator as new-generation photodynamic therapy agent

Proc Natl Acad Sci U S A. 2014 Dec 23;111(51):E5492-7. doi: 10.1073/pnas.1414499111. Epub 2014 Dec 1.

Abstract

In this work, we demonstrate a modality of photodynamic therapy (PDT) through the design of our truly dual-functional--PDT and imaging--gadolinium complex (Gd-N), which can target cancer cells specifically. In the light of our design, the PDT drug can specifically localize on the anionic cell membrane of cancer cells in which its laser-excited photoemission signal can be monitored without triggering the phototoxic generation of reactive oxygen species--singlet oxygen--before due excitation. Comprehensive in vitro and in vivo studies had been conducted for the substantiation of the effectiveness of Gd-N as such a tumor-selective PDT photosensitizer. This treatment modality does initiate a new direction in the development of "precision medicine" in line with stem cell and gene therapies as tools in cancer therapy.

Keywords: gadolinium; imaging; in vivo PDT; survivin; tumor recognition.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • Drug Delivery Systems
  • Gadolinium / therapeutic use*
  • Humans
  • Mice
  • Neoplasms / drug therapy*
  • Photochemotherapy*

Substances

  • Gadolinium